Amgen Comes Out On Top After Bench Trial Over Cancer Drug
Amgen Inc. may have staved off generic competition for its injectable anti-cancer drug Kyprolis for another seven years, after a Delaware federal judge refused to declare a trio of patents tied...To view the full article, register now.
Already a subscriber? Click here to view full article